MedPath
Found 21 clinical trials|View Analysis
Sort by:

This is an Observational Pre-post Study to Observe if the Off Label Use of Anti-IL1 Therapies, Such as Anakinra or Canakinumab, Can Block ACVR1-induced Flare Activity and Heterotopic Ossification in FOP

Not yet recruiting
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
First Posted Date
2024-12-09
Last Posted Date
2024-12-09
Lead Sponsor
University of California, San Francisco
Target Recruit Count
11
Registration Number
NCT06724562
Locations
๐Ÿ‡บ๐Ÿ‡ธ

UCSF, San Francisco, California, United States

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Phase 2
Recruiting
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Drug: Placebo
Drug: Andecaliximab
First Posted Date
2024-07-18
Last Posted Date
2024-12-18
Lead Sponsor
Ashibio Inc
Target Recruit Count
92
Registration Number
NCT06508021
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of California San Francisco (UCSF), San Francisco, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic, Rochester, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States

and more 1 locations

A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Recruiting
Conditions
Fibrodysplasia Ossificans Progressiva
First Posted Date
2023-10-18
Last Posted Date
2024-12-24
Lead Sponsor
Ipsen
Target Recruit Count
70
Registration Number
NCT06089616
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

Edmonton Clinic Health Academy (ECHA)- University of Alberta, Edmonton, Canada

๐Ÿ‡จ๐Ÿ‡ฆ

Bone Research and Education Centre, Oakville, Canada

๐Ÿ‡จ๐Ÿ‡ฆ

University Health Network (UHN) - Toronto General, Toronto, Canada

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Completed
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Other: Non-Interventional
First Posted Date
2023-10-03
Last Posted Date
2023-10-25
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
131
Registration Number
NCT06064656
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Regeneron, Tarrytown, New York, United States

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Phase 3
Active, not recruiting
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Drug: Garetosmab
Drug: Placebo
First Posted Date
2022-05-27
Last Posted Date
2024-11-19
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
63
Registration Number
NCT05394116
Locations
๐Ÿ‡ซ๐Ÿ‡ท

Hรดpital Lapeyronie, Montpellier, France

๐Ÿ‡ฏ๐Ÿ‡ต

Kyushu University Hospital, Fukuoka, Japan

๐Ÿ‡ง๐Ÿ‡ท

Hospital Israelita Albert Einstein, Sao Paulo, Brazil

and more 19 locations

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Phase 2
Recruiting
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Drug: placebo
Drug: INCB000928
First Posted Date
2021-10-25
Last Posted Date
2024-12-10
Lead Sponsor
Incyte Corporation
Target Recruit Count
60
Registration Number
NCT05090891
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of California San Francisco Medical Center, San Francisco, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic Rochester, Rochester, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children'S Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 30 locations

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Phase 2
Active, not recruiting
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Drug: IPN60130
Drug: Placebo
First Posted Date
2021-09-09
Last Posted Date
2024-12-27
Lead Sponsor
Clementia Pharmaceuticals Inc.
Target Recruit Count
98
Registration Number
NCT05039515
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of California San Francisco (UCSF), San Francisco, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic, Rochester, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 22 locations

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged โ‰ฅ14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

Phase 3
Completed
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
First Posted Date
2021-08-30
Last Posted Date
2024-12-27
Lead Sponsor
Ipsen
Target Recruit Count
63
Registration Number
NCT05027802
Locations
๐Ÿ‡ฆ๐Ÿ‡ท

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic, Rochester, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital of Philidelphia, Philadelphia, Pennsylvania, United States

and more 10 locations

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

Phase 1
Completed
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
First Posted Date
2021-04-02
Last Posted Date
2021-04-02
Lead Sponsor
Clementia Pharmaceuticals Inc.
Target Recruit Count
48
Registration Number
NCT04829773
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Cambridge Ipsen US, Cambridge, Massachusetts, United States

Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

Phase 1
Completed
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Drug: DS-6016a
Drug: Placebo
First Posted Date
2021-03-26
Last Posted Date
2022-08-03
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
48
Registration Number
NCT04818398
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan

ยฉ Copyright 2025. All Rights Reserved by MedPath